Bangladesh - englanti - DGDA (Directorate General of Drug Administration)

ad-din pharmaceuticals ltd. - ciprofloxacin - powder for suspension - 250 mg/5 ml

Arabiemiirikunnat - englanti - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

10's blister -

Arabiemiirikunnat - englanti - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

ciprofloxacin hydrochloride 291.1mg equivalent to ciprofloxacin -

Arabiemiirikunnat - englanti - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

ciprofloxacin hydrochloride 873.3mg equivalent to ciprofloxacin -

Arabiemiirikunnat - englanti - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

unicare medical trading l.l.c saudi arabia - 10's blister - tablet - 750mg / tablet - infections-antibacterial

Arabiemiirikunnat - englanti - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

unicare medical trading l.l.c saudi arabia - 10's blister - tablet - 250mg / tablet - infections-antibacterial

Arabiemiirikunnat - englanti - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

unicare medical trading l.l.c saudi arabia - 10's blister - tablet - 500mg / tablet - infections-antibacterial

Malta - englanti - Medicines Authority

s.c. ac helcor pharma s.r.l. 50 victor babes street, baia-mare, maramures, romania - ciprofloxacin - film-coated tablet - ciprofloxacin 250 milligram(s) - antibacterials for systemic use

Malta - englanti - Medicines Authority

s.c. ac helcor pharma s.r.l. 50 victor babes street, baia-mare, maramures, romania - ciprofloxacin - film-coated tablet - ciprofloxacin 500 milligram(s) - antibacterials for systemic use

Australia - englanti - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - ciprofloxacin hydrochloride, quantity: 583 mg (equivalent: ciprofloxacin, qty 500 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; maize starch; crospovidone; colloidal anhydrous silica; magnesium stearate; hypromellose; macrogol 4000; titanium dioxide - ciprofloxacin is indicated for the treatment of infections caused by susceptible organisms in the following conditions listed below: urinary tract infections; gonorrhoeal urethritis and cervicitis; gastroenteritis; bronchial infections; skin and skin structure infections; bone and joint infections; chronic bacterial prostatitis of mild to moderate severity. inhalational anthrax (post exposure): to reduce the incidence or progression of disease following exposure to aerosolized bacillus anthracis. ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. note: typhoid and paratyphoid infections and infections due to multi-resistant staphylococcus aureus are excluded from the above due to insufficient data. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram-positive infections, such as pneumonia due to streptococcus pne